

# Olga Koshelskaya

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5592143/publications.pdf>

Version: 2024-02-01

54  
papers

3,558  
citations

1163117

8  
h-index

552781

26  
g-index

55  
all docs

55  
docs citations

55  
times ranked

4225  
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophages in epicardial adipose tissue and serum NT-proBNP in patients with stable coronary artery disease. <i>Medical Immunology (Russia)</i> , 2022, 24, 389-394.	0.4	1
2	Hypertrophy and Insulin Resistance of Epicardial Adipose Tissue Adipocytes: Association with the Coronary Artery Disease Severity. <i>Biomedicines</i> , 2021, 9, 64.	3.2	19
3	Circulating FoxP3+ T-lymphocytes in chronic coronary artery disease: Associations with the severity of atherosclerosis and lipid metabolism. <i>Sibirskij Zhurnal Klinicheskoy i Eksperimental'noy Meditsiny</i> , 2021, 36, 45-51.	0.4	1
4	SUBCELLULAR LOCALIZATION OF FoxP3 TRANSCRIPTION FACTOR IN PATIENTS WITH ACUTE CORONARY SYNDROME: COMPARATIVE ANALYSIS AND PROSPECTIVE OBSERVATION. <i>Medical Immunology (Russia)</i> , 2021, 23, 731-736.	0.4	0
5	The level of reactive oxygen species production by adipocytes of epicardial adipose tissue is associated with an increase in postprandial glycemia in patients with severe coronary atherosclerosis. <i>Sibirskij Zhurnal Klinicheskoy i Eksperimental'noy Meditsiny</i> , 2021, 36, 59-67.	0.4	2
6	Association of decreased glomerular filtration rate with renal hemodynamic disorders and inflammatory biomarkers in patients with medically-controlled hypertension of high cardiovascular risk. <i>Russian Journal of Cardiology</i> , 2021, 26, 4640.	1.4	2
7	MRI assessment of the abdominal adipose tissue and the state of the abdominal aorta in patients with coronary artery disease: association with metabolic disorders. <i>Bulletin of Siberian Medicine</i> , 2021, 20, 95-104.	0.3	0
8	Frequency of monocyte subsets is linked to the severity of atherosclerosis in patients with ischemic		

#	ARTICLE	IF	CITATIONS
19	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2018, 392, 1519-1529.	13.7	1,179
20	IMMUNOREGULATORY IMBALANCE AND FUNCTIONAL STATE OF THE HEART IN THE PATIENTS WITH DIABETES MELLITUS TYPE 2. <i>Medical Immunology (Russia)</i> , 2018, 20, 833-846.	0.4	4
21	INTERPLAY OF INFLAMMATION AND METABOLIC FACTORS IN COMORBID OBESITY AND ARTERIAL HYPERTENSION OF HIGH AND VERY HIGH RISK. <i>Russian Journal of Cardiology</i> , 2018, , 27-33.	1.4	3
22	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	27.0	1,455
23	[PP.12.26] METABOLIC EFFECTS OF DIFFERENT LIPID-LOWERING THERAPY REGIMENS IN HYPERTENSIVE PATIENTS WITH HIGH CARDIOVASCULAR RISK. <i>Journal of Hypertension</i> , 2017, 35, e193-e194.	0.5	0
24	[PP.18.24] INTRARENAL VASCULAR RESISTANCE AND CIRCADIAN BLOOD PRESSURE PROFILE IN HYPERTENSIVE DIABETIC PATIENTS. <i>Journal of Hypertension</i> , 2017, 35, e237-e238.	0.5	0
25	Visceral obesity and cardiometabolic risk: features of hormonal and immune regulation. <i>Obesity and Metabolism</i> , 2017, 14, 3-10.	1.2	15
26	Prediction of basal glycaemia dynamics during treatment with 6-month lipid-lowering therapy in patients at high risk of cardiovascular disease. <i>Diabetes Mellitus</i> , 2017, 20, 374-383.	1.9	1
27	T-helper-1, T-helper-17, T-regulatory lymphocytes in hypertensive patients with diabetes mellitus type 2 or impaired glucose tolerance: association with clinical and metabolic parameters in a case control study. <i>Translational Medicine Communications</i> , 2016, 1, .	1.4	1
28	PP.05.29. <i>Journal of Hypertension</i> , 2015, 33, e176.	0.5	0
29	PP.05.30. <i>Journal of Hypertension</i> , 2015, 33, e176.	0.5	0
30	PP.05.31. <i>Journal of Hypertension</i> , 2015, 33, e176-e177.	0.5	0
31	Physiological basis of the improvement of movement accuracy on the basis of stabilographic training with biological feedback. <i>Human Physiology</i> , 2015, 41, 404-411.	0.4	1
32	System of Matrix Metalloproteinases and Cytokine Secretion in Type 2 Diabetes Mellitus and Impaired Carbohydrate Tolerance Associated with Arterial Hypertension. <i>Bulletin of Experimental Biology and Medicine</i> , 2014, 156, 635-638.	0.8	15
33	Lipid and pleotropic effects of atorvastatin therapy and its combination with ezetimibe in patients with coronary artery disease and diabetes. <i>Atherosclerosis</i> , 2014, 235, e257.	0.8	0
34	Functional activity of th1-lymphocytes depends on the degree of insulin resistance in patients with diabetes mellitus type 2. <i>Atherosclerosis</i> , 2014, 235, e141.	0.8	0
35	GLYCEMIA CONTROL, INSULIN RESISTANCE, AND FUNCTIONAL ACTIVITY OF T-HELPER SUBPOPULATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. <i>Russian Journal of Cardiology</i> , 2014, , 95-101.	1.4	1
36	FOXP3+T-REGULATORY LYMPHOCYTES AND AUTOANTIBODIES IN PATIENTS WITH ARTERIAL HYPERTENSION, ASSOCIATED WITH DIABETES MELLITUS TYPE 2 AND IMPAIRED GLUCOSE TOLERANCE. <i>Medical Immunology (Russia)</i> , 2014, 15, 155.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Algorithm for differential administration of combination antihypertensive therapy in patients with Type 2 diabetes mellitus. Russian Journal of Cardiology, 2013, , 74-82.	1.4	0
38	EFFECT OF THE COMBINED ANTIHYPERTENSIVE THERAPY WITH TARGET BLOOD PRESSURE ACHIEVEMENT ON INTRARENAL BLOOD FLOW IN PATIENTS WITH TYPE 2 DIABETES. Rational Pharmacotherapy in Cardiology, 2012, 8, 433-440.	0.8	1
39	EFFICACY OF COMBINED ANTIHYPERTENSIVE THERAPY IN ACHIEVEMENT OF TARGET BLOOD PRESSURE IN DIABETIC PATIENTS. Rational Pharmacotherapy in Cardiology, 2012, 8, 667-674.	0.8	0
40	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine, 2011, 365, 2078-2087.	27.0	731
41	DIFFERENT EFFECTS OF TARGET BLOOD PRESSURE ACHIEVED DURING COMBINED ANTIHYPERTENSIVE THERAPY WITH AND WITHOUT RAAS INHIBITORS ON INTRARENAL VASCULAR RESISTANCE IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2011, 29, e398.	0.5	0
42	DYNAMICS OF INTRARENAL VASCULAR RESISTANCE UNDER LONG-TERM ANTIHYPERTENSIVE MONOTHERAPY WITH ACE INHIBITORS AND CALCIUM ANTAGONISTS IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2011, 29, e235.	0.5	0
43	INTRARENAL BLOOD FLOW DOPPLER SPECTRA IN DIABETIC PATIENTS AND HYPERTENSIVE DIABETIC PATIENTS: PP.17.146. Journal of Hypertension, 2010, 28, e294.	0.5	0
44	DISPROPORTIONAL INCREASE IN SYSTOLIC BLOOD PRESSURE AND TARGET ORGAN DAMAGE SIGNS IN HYPERTENSIVE DIABETIC PATIENTS: PP.17.150. Journal of Hypertension, 2010, 28, e295.	0.5	0
45	MS122 LEPTIN CONTENT IN BLOOD SERUM OF WOMEN WITH ISCHEMIC HEART DISEASE AND OBESITY. Atherosclerosis Supplements, 2010, 11, 134.	1.2	2
46	MS453 LIPID AND PLEOTROPIC EFFECTS OF LONG-TERM ATORVASTATIN THERAPY IN HYPERTENSIVE DIABETIC AND NON-DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE. Atherosclerosis Supplements, 2010, 11, 201.	1.2	0
47	ACE and AGTR1 Polymorphisms in Pathogenesis of Human Left Ventricular Hypertrophy. Molecular Biology, 2004, 38, 844-849.	1.3	2
48	HYPOGLYCEMIC THERAPY, VASCULAR FUNCTION AND CYTOKINES. Journal of Hypertension, 2004, 22, S49.	0.5	0
49	TRIMETAZIDINE AND ACE INHIBITORS THERAPY IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2004, 22, S364.	0.5	0
50	EFFECT OF LONG-TERM ACE INHIBITION ON BLOOD PRESSURE PROFILE AND INTRARENAL BLOOD FLOW VELOCITY DOPPLER SPECTRA IN HYPERTENSIVE DIABETIC PATIENTS. Journal of Hypertension, 2000, 18, S106.	0.5	0
51	ABNORMAL CIRCADIAN RHYTHM AND VARIABILITY OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS. Journal of Hypertension, 2000, 18, S45-S46.	0.5	0
52	Quantitative determination of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate in blood serum and plasma by stripping voltammetry. Pharmaceutical Chemistry Journal, 1995, 29, 219-220.	0.8	2
53	Clinical efficacy of cilazapril in patients with essential hypertension and type II diabetes mellitus. Pharmacological Research, 1995, 31, 325.	7.1	0
54	Metabolic effects of Captopril in hypertensive patients with noninsulin-dependent diabetes mellitus and hyperlipidemia. Pharmacological Research, 1995, 31, 325.	7.1	0